Cerasome delivery system for targeting activated CD44 molecule, preparation method and use thereof
A cerasome delivery system for targeting activated cd44 molecule, a preparation method and use thereof: a surface of a cerasome is partially modified by a targeting ligand, the targeting ligand being a ligand which may specifically bind to an activated cd44 molecule. The cerasome delivery system may be used for the diagnosis, prevention and treatment of vulnerable plaque or diseases associated with vulnerable plaque.
1. A cerasome delivery system for targeting an activated CD44 molecule, and wherein the cerasome delivery system comprises a cerasome vesicle, which is a closed vesicle formed by a lipid bilayer having an inner hydrophilic cavity, and wherein the surface of the vesicle has an inorganic polysiloxane reticulate structure, and wherein the lipid bilayer is formed by components including: a cerasome monomer molecule CL1 set forth by formula (I):
a distearoylphosphatidylethanolamine (DSPE) molecule, and distearoylphosphatidylcholine (DSPC), in a weight ratio of 5:2.5:1.5,
wherein the DSPE molecule is coupled through the amino group thereof directly to a targeting ligand by an amide bond on the surface of the cerasome vesicle, and the targeting ligand is capable of specifically binding to the activated CD44 molecule.
2. The cerasome delivery system of claim 1 , wherein the cerasome delivery system is for targeting a vulnerable plaque, and the targeting ligand is capable of specifically binding to a CD44 molecule on a cell surface at the vulnerable plaque.
3. The cerasome delivery system of claim 1 , wherein the particle size of the cerasome vesicle is in the range of 50 nm-400 nm.
4. The cerasome delivery system of claim 1 , wherein the targeting ligand is selected from glycosaminoglycan (G.A.G.), collagen, laminin, fibronectin, selectin, osteopontin (O.P.N.), and monoclonal antibodies HI44a, HI313, A3D8, H90, and IM7; or is selected from a hyaluronic acid or a hyaluronic acid derivative capable of specifically binding to a CD44 molecule on a cell surface at the vulnerable plaque.
5. The cerasome delivery system of claim 1 , wherein the targeting ligand has a molecular weight of 10,000-400,000 Da.
6. The cerasome delivery system of claim 1 , wherein the cerasome is loaded with a substance for diagnosing, preventing, and/or treating the vulnerable plaque or a disease associated with the vulnerable plaque.
7. The cerasome delivery system of claim 6 , wherein the substance is selected from one or more of statins, fibrates, antiplatelet drugs, PCSK9 inhibitors, anticoagulant drugs, angiotensin converting enzyme inhibitors (ACEI), calcium ion antagonists, M.M.P.s inhibitors, β receptor blockers, pharmaceutically acceptable salts thereof, and active structure fragments thereof.
8. The cerasome delivery system of claim 7 , wherein the substance for preventing and/or treating the vulnerable plaque or a disease associated with the vulnerable plaque is selected from one or more of lovastatin, atorvastatin, rosuvastatin, simvastatin, fluvastatin, pitavastatin, pravastatin, bezafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate, probucol, anti-PCSK9 antibodies, antisense RNAi oligonucleotides, nucleic acids, adnectin and the effective fragments or pharmaceutically acceptable salts thereof, one or more of pharmaceutically acceptable salts thereof, and active structure fragments thereof.
9. A medicament, comprising the cerasome delivery system of claim 1 , and one or more pharmaceutically acceptable carriers.